Pillar Biosciences, a Natik, MA-based decision medicine company, raised $34.5M in funding.
Backers included Illumina, Soleus Capital and existing investors.
The company intends to use the funds to advance its commercial activities including headcount and infrastructure to support biopharma partnerships and expand adoption of its distributable clinical testing kits.
Founded by Gang Song, Pillar Biosciences specializes in Decision Medicine, which uses new sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Its NGS testing solutions are powered by its proprietary SLIMamp and PiVAT technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally.
The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development.
FinSMEs
27/05/2025